Back to results
US 2011/0212076 A1Published application
Viral Therapeutic
AssigneesKing's College London, Baylor College of Medicine
InventorsAnnapurna Vyakarnam, David R. Rowley
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneesKing's College London, Baylor College of Medicine
InventorsAnnapurna Vyakarnam, David R. Rowley
Estimating the term…
The invention provides a method of inhibiting viral infection of a mammalian cell, said method comprising reducing or inhibiting ps20 polypeptide expressed by said cell. Suitably ps20 is inhibited by contacting said cell with an antibody capable of binding to ps20 polypeptide. Suitably said antibody is ps20 neutralising antibody. The invention also provides antibody capable of binding ps20 polypeptide, siRNA targeted to a transcript encoding ps20 polypeptide, or antisense ps20 polynucleotide for use as a medicament for viral infection. The invention also provides a method of identifying an agent for inhibiting a viral infection, comprising determining level of ps20 expression in first and second samples, the first contacted with test agent; and comparing the level of ps20 expression in said first and second samples; wherein lower level of ps20 expression in said first sample relative to said second sample identifies test agent as an agent for inhibiting a viral infection.
A method of inhibiting viral infection of a mammalian cell, said method comprising reducing or inhibiting ps20 polypeptide expressed by said cell.
A composition comprising an antibody capable of binding ps20 polypeptide, siRNA targeted to a transcript encoding a ps20 polypeptide, or antisense ps20 polynucleotide wherein said composition reduces viral infection.
A method of treating viral infection in a subject comprising administering to said subject a composition comprising an antibody capable of binding ps20 polypeptide, siRNA targeted to a transcript encoding a ps20 polypeptide, or antisense ps20 polynucleotide in an amount effective to treat viral infection in said subject.
(canceled)
(canceled)
A method of treating or preventing viral infection in a subject, said method comprising reducing or inhibiting ps20 polypeptide in said subject.
A method of rendering a cell resistant to human immunodeficiency virus infection, said method comprising contacting said cell with ps20 neutralising antibody.
A method of identifying an agent for inhibiting a viral infection the method comprising
A method of rendering a cell permissive of viral infection, said method comprising inducing ps20 expression in said cell.
A method of rendering a cell permissive of viral infection, said method comprising contacting said cell with a ps20 polypeptide.
A method of inducing expression of LFA-1 in a cell, said method comprising inducing ps20 expression in said cell.
A method of inducing expression of CD54 in a cell, said method comprising inducing ps20 expression in said cell.
Dependencies are inferred from the claim text.